These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

846 related items for PubMed ID: 31637956

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Drug-coated balloons vs. drug-eluting stents for treatment of long femoropopliteal lesions.
    Zeller T, Rastan A, Macharzina R, Tepe G, Kaspar M, Chavarria J, Beschorner U, Schwarzwälder U, Schwarz T, Noory E.
    J Endovasc Ther; 2014 Jun; 21(3):359-68. PubMed ID: 24915582
    [Abstract] [Full Text] [Related]

  • 4. Directional Atherectomy With Antirestenotic Therapy vs Drug-Coated Balloon Angioplasty Alone for Isolated Popliteal Artery Lesions.
    Stavroulakis K, Schwindt A, Torsello G, Stachmann A, Hericks C, Bosiers MJ, Beropoulis E, Stahlhoff S, Bisdas T.
    J Endovasc Ther; 2017 Apr; 24(2):181-188. PubMed ID: 28008792
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Paclitaxel-Coated Balloon vs Uncoated Balloon Angioplasty for Treatment of In-Stent Restenosis in the Superficial Femoral and Popliteal Arteries: The COPA CABANA Trial.
    Tepe G, Schroeder H, Albrecht T, Reimer P, Diehm N, Baeriswyl JL, Brechtel K, Speck U, Zeller T.
    J Endovasc Ther; 2020 Apr; 27(2):276-286. PubMed ID: 32096451
    [Abstract] [Full Text] [Related]

  • 8. Paclitaxel-Eluting Balloon Versus Standard Balloon Angioplasty in In-Stent Restenosis of the Superficial Femoral and Proximal Popliteal Artery: 1-Year Results of the PACUBA Trial.
    Kinstner CM, Lammer J, Willfort-Ehringer A, Matzek W, Gschwandtner M, Javor D, Funovics M, Schoder M, Koppensteiner R, Loewe C, Ristl R, Wolf F.
    JACC Cardiovasc Interv; 2016 Jul 11; 9(13):1386-92. PubMed ID: 27388828
    [Abstract] [Full Text] [Related]

  • 9. Primary Patency of Long-Segment Femoropopliteal Artery Lesions in Patients with Peripheral Arterial Occlusive Disease Treated with Paclitaxel-Eluting Technology.
    Phair J, Carnevale M, Lipsitz EC, Shariff S, Scher L, Garg K.
    Ann Vasc Surg; 2020 Jul 11; 66():595-600. PubMed ID: 31863948
    [Abstract] [Full Text] [Related]

  • 10. Vessel Calcification as a Risk Factor for In-Stent Restenosis in Complex Femoropopliteal Lesions After Zilver PTX Paclitaxel-Coated Stent Placement.
    Ichihashi S, Shibata T, Fujimura N, Nagatomi S, Yamamoto H, Kyuragi R, Adachi A, Iwakoshi S, Bolstad F, Saeki K, Obayashi K, Kichikawa K.
    J Endovasc Ther; 2019 Oct 11; 26(5):613-620. PubMed ID: 31257994
    [Abstract] [Full Text] [Related]

  • 11. Six-Month Results From the Initial Randomized Study of the Ranger Paclitaxel-Coated Balloon in the Femoropopliteal Segment.
    Bausback Y, Willfort-Ehringer A, Sievert H, Geist V, Lichtenberg M, Del Giudice C, Sauguet A, Diaz-Cartelle J, Marx C, Ströbel A, Schult I, Scheinert D, RANGER SFA Investigators.
    J Endovasc Ther; 2017 Aug 11; 24(4):459-467. PubMed ID: 28558502
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Drug-Coated Balloon Treatment for Femoropopliteal Artery Disease: The IN.PACT Global Study De Novo In-Stent Restenosis Imaging Cohort.
    Brodmann M, Keirse K, Scheinert D, Spak L, Jaff MR, Schmahl R, Li P, Zeller T, IN.PACT Global Study Investigators.
    JACC Cardiovasc Interv; 2017 Oct 23; 10(20):2113-2123. PubMed ID: 29050631
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. A Pilot Study of Femoropopliteal Artery Revascularisation with a Low Dose Paclitaxel Coated Balloon: Is Predilatation Necessary?
    Schroeder H, Meyer DR, Lux B, Ruecker F, Martorana M, Miller LE, Duda S.
    Eur J Vasc Endovasc Surg; 2017 Sep 23; 54(3):348-355. PubMed ID: 28778456
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. First-in-man experience of self-expanding nitinol stents combined with drug-coated balloon in the treatment of femoropopliteal occlusive disease.
    Mwipatayi BP, Perera K, Daneshmand A, Daniel R, Wong J, Thomas SD, Burrows SA.
    Vascular; 2018 Feb 23; 26(1):3-11. PubMed ID: 28436316
    [Abstract] [Full Text] [Related]

  • 18. German Center Subanalysis of the LEVANT 2 Global Randomized Study of the Lutonix Drug-Coated Balloon in the Treatment of Femoropopliteal Occlusive Disease.
    Scheinert D, Schmidt A, Zeller T, Müller-Hülsbeck S, Sixt S, Schröder H, Weiss N, Ketelsen D, Ricke J, Steiner S, Rosenfield K.
    J Endovasc Ther; 2016 Jun 23; 23(3):409-16. PubMed ID: 27117972
    [Abstract] [Full Text] [Related]

  • 19. Three-Year Sustained Clinical Efficacy of Drug-Coated Balloon Angioplasty in a Real-World Femoropopliteal Cohort.
    Torsello G, Stavroulakis K, Brodmann M, Micari A, Tepe G, Veroux P, Benko A, Choi D, Vermassen FEG, Jaff MR, Guo J, Dobranszki R, Zeller T, IN.PACT Global Investigators.
    J Endovasc Ther; 2020 Oct 23; 27(5):693-705. PubMed ID: 32583749
    [Abstract] [Full Text] [Related]

  • 20. Randomized comparison of femoropopliteal artery drug-eluting balloons and drug-eluting stents (FOREST trial): Study protocol for a randomized controlled trial.
    Jongsma H, van Mierlo-van den Broek P, Imani F, van den Heuvel D, de Vries JPM, Fioole B.
    J Vasc Surg; 2017 Oct 23; 66(4):1293-1298. PubMed ID: 28826727
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 43.